Insights

Innovative Platform Eikon Therapeutics employs cutting-edge microscopy technology that enables highly sensitive detection of protein-drug interactions in live cells, offering a competitive advantage in early drug discovery and a potential market for advanced scientific instrumentation and reagent providers.

Strong Funding Backing With a recent Series D investment of over 351 million dollars led by Soros Capital Management, Eikon has significant financial resources to accelerate clinical development and expand partnerships, creating opportunities for strategic collaborations in biotechnology and pharmaceutical sectors.

Pipeline Development Eikon is progressing rapidly with a lead candidate, EIK1001, for non-small cell lung cancer set for Phase II/III trials, indicating potential for partnerships in clinical research, trial services, and specialized medical equipment.

Leadership Expansion Recent key hires, including a COO and strategic board members, suggest Eikon is scaling its operational capabilities, presenting possibilities for B2B opportunities in consulting, operational support, and enterprise technology solutions.

Market Positioning Positioned in the competitive biotech landscape with around 200-500 employees and revenue up to 250 million dollars, Eikon is poised for growth, making it a promising partner for companies seeking innovative biology-enabled drug discovery collaborations.

Eikon Therapeutics Tech Stack

Eikon Therapeutics uses 8 technology products and services including GDPR, Cloudflare, Selenium, and more. Explore Eikon Therapeutics's tech stack below.

  • GDPR
    Certificates
  • Cloudflare
    Content Management System
  • Selenium
    Frameworks And Libraries
  • Vue.js
    Javascript Frameworks
  • Lenis
    Javascript Libraries
  • Planisware
    Project Management
  • Yoast SEO
    Search Engines
  • Autodesk
    Visualisation Software

Media & News

Eikon Therapeutics's Email Address Formats

Eikon Therapeutics uses at least 1 format(s):
Eikon Therapeutics Email FormatsExamplePercentage
LastF@eikontx.comDoeJ@eikontx.com
62%
First@eikontx.comJohn@eikontx.com
17%
First.Last@eikontx.comJohn.Doe@eikontx.com
12%
LF@eikontx.comDJ@eikontx.com
9%

Frequently Asked Questions

Where is Eikon Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Eikon Therapeutics's main headquarters is located at 3929 Point Eden Way, Hayward, CA 94545, US. The company has employees across 4 continents, including North AmericaEuropeAfrica.

What is Eikon Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Eikon Therapeutics's official website is eikontx.com and has social profiles on LinkedInCrunchbase.

What is Eikon Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Eikon Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Eikon Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2025, Eikon Therapeutics has approximately 386 employees across 4 continents, including North AmericaEuropeAfrica. Key team members include Chief Business Officer & General Counsel: B. T.Chief Operating Officer: M. K.Chief People Officer: B. H.. Explore Eikon Therapeutics's employee directory with LeadIQ.

What industry does Eikon Therapeutics belong to?

Minus sign iconPlus sign icon
Eikon Therapeutics operates in the Biotechnology Research industry.

What technology does Eikon Therapeutics use?

Minus sign iconPlus sign icon
Eikon Therapeutics's tech stack includes GDPRCloudflareSeleniumVue.jsLenisPlaniswareYoast SEOAutodesk.

What is Eikon Therapeutics's email format?

Minus sign iconPlus sign icon
Eikon Therapeutics's email format typically follows the pattern of LastF@eikontx.com. Find more Eikon Therapeutics email formats with LeadIQ.

How much funding has Eikon Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2025, Eikon Therapeutics has raised $351M in funding. The last funding round occurred on Feb 26, 2025 for $351M.

When was Eikon Therapeutics founded?

Minus sign iconPlus sign icon
Eikon Therapeutics was founded in 2019.

Eikon Therapeutics

Biotechnology ResearchUnited States201-500 Employees

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. 

By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. 

Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit:  https://www.eikontx.com/join-us/#open-positions

Section iconCompany Overview

Headquarters
3929 Point Eden Way, Hayward, CA 94545, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
201-500

Section iconFunding & Financials

  • $351M

    Eikon Therapeutics has raised a total of $351M of funding over 5 rounds. Their latest funding round was raised on Feb 26, 2025 in the amount of $351M.

  • $100M$250M

    Eikon Therapeutics's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $351M

    Eikon Therapeutics has raised a total of $351M of funding over 5 rounds. Their latest funding round was raised on Feb 26, 2025 in the amount of $351M.

  • $100M$250M

    Eikon Therapeutics's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.